Obesity Today—April 7, 2026

LucidQuest

4 hours ago

This week’s Obesity update highlights regulatory progress, advancing late-stage development, mixed clinical readouts, pricing shifts, and continued investment in next-generation treatment approaches.

In this Newsletter

Dive deeper

💊 Eli Lilly wins FDA approval for Foundayo (orforglipron) [1] [US • 01 Apr 2026]

https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html
Context: Foundayo (orforglipron, Eli Lilly; oral GLP-1) was approved for adults with obesity, or overweight with weight-related medical problems, alongside diet and physical activity.
Key point: Lilly said Foundayo is the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, and cited ATTAIN-1 data showing 12.4% average weight loss at the highest dose among participants who stayed on treatment.
Implication: May influence prescriber choice and payer reviews pending full data.

📊 Novo Nordisk positions Wegovy pill ahead of orforglipron in indirect comparison [2] [US • 02 Apr 2026]

https://www.prnewswire.com/news-releases/wegovy-pill-demonstrated-greater-weight-loss-than-orforglipron-and-lower-odds-of-stopping-medication-due-to-side-effects-in-a-new-indirect-comparison-to-be-presented-at-obesity-medicine-association-2026-302732762.html
Context: ORION compared oral semaglutide 25 mg with orforglipron 36 mg using data from OASIS 4 and ATTAIN-1, adjusted for baseline body weight, glycemic status, and sex.
Key point: Novo Nordisk reported greater mean weight loss and lower odds of discontinuation due to adverse events for Wegovy pill versus orforglipron in a population-adjusted indirect treatment comparison, while noting limits from between-trial differences and low event counts.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧪 ACC 2026 meta-analysis backs CagriSema as first-line obesity option [3] [US • 28 Mar 2026]

https://www.clinicaltrialsarena.com/analyst-comment/acc-2026-cagrisema-superior-first-line-obesity-therapy-meta-analysis/
Context: The Bayesian network meta-analysis drew on randomized controlled trial data from five databases, covering 2,803 adults with overweight or obesity.
Key point: The analysis presented at ACC 2026 supported CagriSema (Novo Nordisk; cagrilintide plus semaglutide) over semaglutide 2.4 mg and cagrilintide alone on efficacy, safety, and tolerability positioning.
Implication: May influence prescriber choice and payer reviews pending full data.

🌏 Innogen highlights efsubaglutide α as obesity catalyst after first commercial year [4] [01 Apr 2026]

https://firstwordpharma.com/story/7156810
Context: Innogen said efsubaglutide α generated first-year revenue in type 2 diabetes, has NRDL inclusion in China, and ended 2025 with reported cash and cash equivalents of RMB 969 million.
Key point: The company framed obesity as its main value inflection point, said its China Phase III obesity trial has completed enrollment, and expects topline efficacy and safety data before year-end 2026.
Implication: Signals pipeline investment and modality expansion.

🇰🇷 Hanmi Pharmaceutical posts record revenue, advances obesity pipeline [5] [South Korea • 31 Mar 2026]

https://www.thelec.net/news/articleView.html?idxno=6205
Context: Hanmi reported 2025 consolidated revenue of 1.5475 trillion won, with R&D spending of 229.0 billion won, and highlighted obesity and metabolic disease as a key focus area.
Key point: Hanmi said efpeglenatide is targeted for commercialization in the second half of 2026, while HM15275 and HM17321 have entered Phase 2 and Phase 1 trials in the US.
Implication: Signals pipeline investment and modality expansion.

🏭 West expands Dublin capacity for high-volume GLP-1 injectables [6] [EU • 31 Mar 2026]

https://investor.westpharma.com/news-releases/news-release-details/west-expands-dublin-facility-support-high-volume-injectable
Context: West Pharmaceutical Services opened a 165,000 square foot expansion at its Damastown, Dublin site under the West Vantage contract services business.
Key point: West said the site adds advanced automation and expanded drug-handling capabilities at commercial scale to support high-volume injectable therapies, including diabetes and obesity treatments.
Implication: May expand screening, initiation, and follow-up at scale.

Why it matters

Eli Lilly’s Foundayo approval [1] turns oral obesity treatment into a commercial reality in the US, with convenience positioned as a key differentiator.
Novo Nordisk is responding with comparative framing for oral semaglutide, but the current evidence cited here is indirect rather than head-to-head [2].
CagriSema continues to build evidence for combination therapy leadership as Novo Nordisk broadens the obesity treatment stack beyond semaglutide alone [3].
Asian developers including Innogen and Hanmi are pushing differentiated GLP-1 strategies, from ultra-long-acting dosing to muscle-focused obesity programs [4][5].
Manufacturing and device capacity are becoming strategic bottlenecks, which makes supplier expansions such as West’s Dublin investment relevant to market access and supply continuity [6].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Obesity archive on our research hub page

FAQ

What is Foundayo, and who is launching it?

Foundayo is Eli Lilly’s brand for orforglipron, an oral GLP-1 approved by the FDA for adults with obesity, or overweight with weight-related medical problems. Lilly said shipping via LillyDirect begins 06 Apr 2026 [1].

Is Novo Nordisk’s Wegovy pill directly proven to beat orforglipron?

Not from the material provided here. Novo Nordisk cited an indirect treatment comparison, ORION, using separate trials rather than a head-to-head study, and the company itself noted cross-trial limitations [2].

What does the ACC 2026 analysis say about CagriSema?

The Clinical Trials Arena item says a Bayesian network meta-analysis supported CagriSema over semaglutide 2.4 mg and cagrilintide for efficacy, safety, and tolerability positioning in adults with overweight or obesity [3].

Why is Innogen’s efsubaglutide α drawing attention?

Innogen is pairing early type 2 diabetes commercialization with a longer-acting GLP-1 profile and a pending obesity opportunity. The company said its China Phase III obesity study is fully enrolled, with topline data expected before year-end 2026 [4].

What is Hanmi’s near-term obesity catalyst?

Hanmi said efpeglenatide is targeted for commercialization in the second half of 2026. It also highlighted follow-on obesity assets HM15275 and HM17321 in US clinical development [5].

Why does West’s Dublin expansion matter to obesity drug makers?

West’s added capacity is aimed at high-volume injectable therapies, including next-generation GLP-1 medicines. That makes it relevant for supply, device assembly, packaging, and commercialization support as obesity demand scales [6].

Entities / Keywords

Foundayo: orforglipron, Eli Lilly, Lilly, oral GLP-1, ATTAIN-1, LillyDirect
Wegovy pill: oral semaglutide 25 mg, Novo Nordisk, ORION, OASIS 4, OPTIC
CagriSema: cagrilintide plus semaglutide, Novo Nordisk, ACC 2026, Bayesian network meta-analysis
Efsubaglutide α: Innogen, ultra-long-acting GLP-1 receptor agonist, Q2W, Q4W, NRDL
Hanmi obesity pipeline: efpeglenatide, HM15275, HM17321, Hanmi Pharmaceutical
West Vantage: West Pharmaceutical Services, Dublin, Damastown, injectable drug delivery, GLP-1 manufacturing support